Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
Verrica Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting record U.S. YCANTH net product revenue of $5.7 million. The company completed enrollment for the first pivotal trial in its Phase 3 common warts program and secured full access to $27.5 million in non-dilutive growth capital, extending its cash runway. Verrica is also exploring the development of VP-315 for Gorlin syndrome, a rare genetic disease.
Put this headline into context
Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.
Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.